Thank you for submitting your manuscript to the EMBO Journal. Your manuscript has now been seen by three referees and their comments to the authors are provide below. As you can see, referees #1 and 3 are both very positive about your study and find that it provides important new insight. However, they also find that some further analysis is needed. Referee #2, on the other hand, is not persuaded that the advance provided is sufficient to consider publication in the EMBO Journal. In order to get further input on the overall assessment provided by referee #2, I also sought further editorial advice on the study. However, the advisor was in agreement with referees #1 and 3 and finds the analysis very interesting. Given all the available input, I would like to ask you to submit a suitably revised manuscript that takes the concerns raised by referees #1 and 3 into account. I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal
REFEREE REPORTS ------------------------------------------------Referee #1 (Remarks to the Author):
This is a concise, well written paper with important new findings regarding how the oncogenic phosphatase Wip1 affects the G2 checkpoint. It was believed that Wip1 reversed the G2 checkpoint primarily through dephosphorylation of key checkpoint proteins such as ATM, Chk2, p53, etc. Here, the authors show that a key part of Wip1 function in G2 checkpoint control is to maintain G2 competence in a p53 dependent manner by preventing downregulation of key mitotic progression genes such as cyclin B1 and Plk1.
The findings described here are novel and should be of some interest to those in the p53, Wip1, and cell cycle checkpoint fields. There is overall enthusiasm for the manuscript, though a few minor revisions could be made.
(1) Title: The cognoscenti may understand what the title is indicating, but the general reader may have some trouble deciphering the main message. More specificity would be helpful here. (e.g. that Wip1 is a phosphatase, G2 is involved, the effect is p53 dependent, and that the effect is on p53 transcriptional targets involved in G2 competence).
(2) Abstract: Why not mention cyclin B1 and Plk1 here to provide a bit more information.
(3) Introduction: The introduction is concise, but maybe too concise. The introduction to Wip1 is good, but the idea of G2 recovery competence will be novel for many people and was only cursorily described. (7) Discussion: In the paper and discussion, the authors show that Wip1 is required throughout a DNA damage response in G2 to allow for eventual checkpoint recovery. But no hypothetical mechanism is proposed for how Wip1 might affect p53 in this way. Not necessary, but it might have been more thought provoking.
Referee #2 (Remarks to the Author):
The authors have investigated the role played by the Wip1 phosphatase in regulating the recovery from cell cycle arrested caused by induction of DNA damage. Their work is primarily conducted in U2OS cells looking at impact on cell cycle progression and expression of cell cycle regulated genes like Cyclin B and Plk1. The authors overly emphasize their finding of a "first in class" recovery competence gene. Frankly, in my opinion the story is somewhat banal and not warranting publication in the EMBO journal. As the authors also state, Wip1 substrates include protein such as ATM, p53, mdm2 and others. It is reasonable to expect therefore that by antagonizing the function of Wip1, one can observe an impact on checkpoint recovery. That is indeed what the authors find and this result is in line with other recently published work. I don't frankly see any "paradox": we have a phosphatase that antagonizes the function of cell cycle checkpoint proteins. Inhibition of both kinases and phosphatase will lead to different downstream effects depending on the rates of phosphorylation and dephosphorylation of their substrate(s). An additional limitation of this work is the failure to investigate the impact of inhibiting Wip1 in multiple pathophysiologically relevant systems, including in vivo ones.
Referee #3 (Remarks to the Author):
In this manuscript Lindqvist et al. have investigated the role of the Wip1 phosphatase in regulating recovery from DNA damage-induced cell cycle arrest. Rather than promoting cell cycle re-entry by simply dephosphorylating targets of checkpoint kinases at the end of the checkpoint response, the authors find that Wip1 must be present throughout the arrest to antagonize p53-mediated transcriptional repression of key mitotic inducers such as Cyclin B and Plk1, ensuring that their protein levels are kept sufficiently high to support a recovery-competent state of the cells once the checkpoint is lifted. This is an interesting story. The concept of recovery competence is novel, the experiments are generally well executed and support the conclusions. However, I suggest the following points to be addressed before recommending the manuscript for publication in EMBO J:
1. In addition to Wip1, a number of phosphatases including PP2A and PP4 have been shown to promote checkpoint recovery by dephosphorylating -H2AX following DNA damage. Because the exact mechanism by which Wip1 promotes recovery competence is unclear, it is important to know whether these phosphatases could also play a role in ensuring such competence or whether this ability is unique to Wip1 through its engagement in regulatory feedback loops with p53. Some of the key experiments demonstrating the recovery competence potential of Wip1 (such as Fig. 1F ) should be performed with at least one of these independent phosphatases. Fig. 1F , the authors state that the inability of checkpoint kinase inhibitors to promote checkpoint recovery in Wip1-depleted cells means that the role of Wip1 is not merely to dephosphorylate and inactivate checkpoint kinases. In order to rigorously make this claim and separate these functions of Wip1, the authors need to verify that phosphorylation of checkpoint kinases and their targets are in fact decreased after combined kinase inhibitor and Wip1 shRNA treatment.
Based in part on
3. It is unclear to me what exactly the authors mean by a "G2 identity" or "G2 state" of a cell, terms used frequently throughout the manuscript. This should be more clearly defined in the text.
4. Figure 5 seems somewhat premature and needs to be further developed. For instance, since microinjection of Cyclin B in the presence of Cdc25B S323G is sufficient to overcome the recovery defect in Wip1-depleted cells, do the authors mean to say that Plk1 (for which they have previously established an important role in recovery from DNA damage-induced cell cycle arrest) is dispensable for checkpoint recovery under these conditions? The effect of microinjection of Plk1 on recovery should be tested. The experiment in Fig. 5B would also benefit from the inclusion of additional controls, such as microinjection of inactive Cdc25B or a Cdk1 mutant (T14A/Y15F) refractory to inhibitory phosphorylation. If the authors are right, the latter protein should not be able to promote mitotic entry in Wip1-depleted cells, thus strengthening the idea that Cyclin B levels are rate-limiting for checkpoint recovery under these conditions. We thank the referee for the constructive review. We have addressed the raised issues and think that this has improved the quality of the manuscript.
(1 We have changed the title to: "Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression".
We have now mentioned Plk1 and Cyclin B in the abstract.
(3) Introduction: The introduction is concise, but maybe too concise. The introduction to Wip1 is good, but the idea of G2 recovery competence will be novel for many people and was only cursorily described.
We have extended the introduction on checkpoint recovery competence.
(4) Figure 1: In panel D, western blots showing to show that Wip1 levels correlated with the observed effects would have been helpful here. In panel F, is there a "no inhibitor" control available to demonstrate inhibitor efficacy?
We have included a western blot in panel D, showing both endogenous and reconstituted Wip1 levels. We have also included a no inhibitor control in panel F.
(5) Supp. Figure 1: The staining of the GFP-Wip1 plasmid is cytoplasmic, which seems strange, because Wip1 historically is always nuclear.
Indeed, we find that GFP-Wip1 is nuclear. However, in this experiment we co-injected an empty GFP plasmid together with FLAG-NT-Wip1 to mark successfully injected cells. We have reformulated the figure legend to make this clearer.
(6) Supp. Figure 2: Not sure this figure adds a lot of value. Is important additional information provided here?
We agree that it is not a crucial figure for the main message. This is why we chose to include it as supplemental data. However, the reduction of Plk1, and to some extent Cyclin B, in untreated Wip1 RNAi HCT116 cells (Fig 4A) , may raise questions among readers. This supplemental figure shows that HCT116 cells experience DNA-damage signalling in the absence of external DNA-damage, explaining the finding in figure 4A . We do speculate that Wip1 functions by regulating p53-ATM oscillations. We also speculate that the function of these oscillations could be to give a cell breathing pauses from the checkpoint that would allow for transcription of mitotic inducers to prevent a cell from loosing its G2-state.
Referee #2 (Remarks to the Author):
The We thank the referee for the constructive review. We have addressed the raised issues and think that this has improved the quality of the manuscript. Fig. 1F ) should be performed with at least one of these independent phosphatases.
In addition to
We have included a figure showing that although PP4 contributes to checkpoint recovery, it is not necessary for accumulation of high Cyclin B levels during a DNA-damage arrest in G2 (New supplementary figure 5 ). We get similar results after transfection of PP2A siRNA. However, we are unable to confirm the knockdown of PP2A and therefore prefer not to include these data in the manuscript. Fig. 1F We have included a figure showing that the ATM/ATR target p53 S15 and the Chk1/Chk2 target p53 S20 are dephosphorylated after combined inhibitor treatment and Wip1 RNAi, showing that these checkpoint kinases are indeed inhibited by the combined inhibitor treatment (new figure 1G) .
Based in part on

It is unclear to me what exactly the authors mean by a "G2 identity" or "G2 state" of a cell, terms used frequently throughout the manuscript. This should be more clearly defined in the text.
We have extended the section on G2 identity in the introduction. Figure 5 We have expanded this figure by microinjecting GFP-Cdk1 AF, as suggested by the reviewer (new figure 5B) . We find that similar to YFP-Cdc25B S323G injections, GFP-Cdk1 AF efficiently induces mitotic entry in control, but not in Wip1 shRNA transfected DNA-damaged G2 cells. Indeed, Plk1 is not necessary for checkpoint recovery if Cyclin B-Cdk1 is artificially activated, either by expression of Cdc25B S323G or Cdk1 AF. This is not surprising since Plk1 largely promotes recovery by activating Cyclin B-Cdk1 (Lindqvist et al, JCB 2009, 185(2):193-202) . In fact, injection of Cdc25B S323G can induce checkpoint recovery after Plk1 depletion, further supporting this notion (data not shown). Although Plk1 is necessary for checkpoint recovery, we find that injection of Plk1 is not sufficient to induce checkpoint recovery. We now discuss this at page 13. We have included a figure where we show that both Plk1 and Cyclin B1 mRNA levels are reduced after doxorubicin treatment in G2 (new supplementary figure 2 ). We now discuss this possibility on page 16 and mention this study in the introduction.
4.
The findings in this manuscript
How did the authors come across Wip1? Was it found in a screen?
We indeed found Wip1 in a small shRNA-based screen. However, the screen was far from complete, and we estimate that approximately 50% of the pools failed to properly downregulate their targets. Therefore we prefer not to publish the raw data, as it might provide a very misleading picture.
Decision letter 29 July 2009
Thank you for submitting your revised manuscript to the EMBO Journal. I asked the original referee #3 to review the revised version and I have now heard back from this referee. As you can see below, this referees is satisfied with the revisions and supports publication here. I am therefore very pleased to proceed with the acceptance of the study. You will receive the formal acceptance letter shortly.
Best wishes Editor
Referee #3
The authors have satisfactorily addressed the points I raised in the first review, and the manuscript is now sufficiently adapted to recommend publication in EMBO Journal.
